Skip to main content
Erschienen in: Journal of Cancer Education 4/2011

01.12.2011

Lung Cancer Patients’ Decisions About Clinical Trials and the Theory of Planned Behavior

verfasst von: Gwendolyn P. Quinn, PhD, Christie L. Pratt, MA, DHSc, Kathy Bryant-George, Vicki D. Caraway, RN, BSN, MBA, Bonnie Paternoster, RN, BSN, MSN, Tere Roldan, MA, CT, Andrea Shaffer, ARNP, AOCNP, Cynthia O. Shimizu, LCSW, MABMH, Elizabeth J. Vaughn, RN, MS, OCN, CCRC, Charles Williams, MD, Gerold Bepler, MD PhD

Erschienen in: Journal of Cancer Education | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

The theory of planned behavior explores the relationship between behavior, beliefs, attitudes, and intentions presupposing that behavioral intention is influenced by a person’s attitude about the behavior and beliefs about whether individuals, who are important to them, approve or disapprove of the behavior (subjective norm). An added dimension to the theory is the idea of perceived behavioral control, or the belief that one has control over performing the behavior. The theory of planned behavior suggests that people may make greater efforts to perform a behavior if they feel they have a high level of control over it. In this examination of data, we explored the application of the theory of planned behavior to patient’s decisions about participating in a clinic trial. Twelve respondents in this study had previously participated in a clinical trial for lung cancer and nine respondents had declined a clinical trial for lung cancer. The data were analyzed with regard to the four constructs associated with the theory of planned behavior: behavioral intention, attitude, subjective norm, and perceived behavioral control. Results indicate that the theory of planned behavior may be a useful tool to examine psychosocial needs in relation to behavioral intention of clinical trial participation.
Literatur
1.
Zurück zum Zitat American Cancer Society (2009) Cancer facts & figures 2009. American Cancer Society, Atlanta American Cancer Society (2009) Cancer facts & figures 2009. American Cancer Society, Atlanta
2.
Zurück zum Zitat Quinn GP, Bell BA, Bell MY et al (2007) The guinea pig syndrome: improving clinical trial participation among thoracic patients. J Thorac Oncol 2(3):191–196PubMedCrossRef Quinn GP, Bell BA, Bell MY et al (2007) The guinea pig syndrome: improving clinical trial participation among thoracic patients. J Thorac Oncol 2(3):191–196PubMedCrossRef
3.
Zurück zum Zitat Lara P, Higdon R, Lim N, Kwan K, Tanaka M, Lau D, Wun T, Welborn J, Meyers F, Christensen S, O’Donnell R, Richman C, Scrudder S, Tuscano J, Gandara D, Lam K (2001) Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 19(6):1728–1733PubMed Lara P, Higdon R, Lim N, Kwan K, Tanaka M, Lau D, Wun T, Welborn J, Meyers F, Christensen S, O’Donnell R, Richman C, Scrudder S, Tuscano J, Gandara D, Lam K (2001) Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 19(6):1728–1733PubMed
4.
Zurück zum Zitat Albrecht T, Eggly S, Gleason M, Harper F, Foster T, Peterson A, Orom H, Penner L, Ruckdeschel J (2008) Influence of clinical communication on patients’ decision making on participation in clinical trials. J Clin Oncol 26(16):2666–2673PubMedCrossRef Albrecht T, Eggly S, Gleason M, Harper F, Foster T, Peterson A, Orom H, Penner L, Ruckdeschel J (2008) Influence of clinical communication on patients’ decision making on participation in clinical trials. J Clin Oncol 26(16):2666–2673PubMedCrossRef
5.
Zurück zum Zitat Klabunde C, Springer B, Butler B et al (1999) Factors influencing enrollment in clinical trials for cancer treatment. South Med Journal 92:1189–1193CrossRef Klabunde C, Springer B, Butler B et al (1999) Factors influencing enrollment in clinical trials for cancer treatment. South Med Journal 92:1189–1193CrossRef
6.
Zurück zum Zitat Comis R, Miller J, Aldige C, Krebs L, Stoval E (2003) Public attitudes toward participation in cancer clinical trials. J Clin Oncol 21(5):830–835PubMedCrossRef Comis R, Miller J, Aldige C, Krebs L, Stoval E (2003) Public attitudes toward participation in cancer clinical trials. J Clin Oncol 21(5):830–835PubMedCrossRef
7.
Zurück zum Zitat Ajzen I (1988) Attitudes, personality, and behavior. Dorsey, Chicago Ajzen I (1988) Attitudes, personality, and behavior. Dorsey, Chicago
8.
Zurück zum Zitat Ajzen I (1991) The theory of planned behavior. Organ Behav Hum Decis Process 50:179–211CrossRef Ajzen I (1991) The theory of planned behavior. Organ Behav Hum Decis Process 50:179–211CrossRef
9.
Zurück zum Zitat Fishbein M, Azjen I (1975) Belief, attitude, intention and behavior: an introduction to theory and research. Addison-Wesley, Reading Fishbein M, Azjen I (1975) Belief, attitude, intention and behavior: an introduction to theory and research. Addison-Wesley, Reading
10.
Zurück zum Zitat Ajzen I (1985) From intentions to actions: a theory of planned behavior. In: Kuhl J, Beckmann J (eds) Action control: from cognition to behavior. Springer, Berlin Ajzen I (1985) From intentions to actions: a theory of planned behavior. In: Kuhl J, Beckmann J (eds) Action control: from cognition to behavior. Springer, Berlin
11.
Zurück zum Zitat Ellis P, Butow P, Tattersall M, Dunn S, Houssami N (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 19:3554–3561PubMed Ellis P, Butow P, Tattersall M, Dunn S, Houssami N (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 19:3554–3561PubMed
12.
Zurück zum Zitat Gattellari M, Voigt K, Butow P, Tattersall M (2002) When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J Clin Oncol 20:503–513PubMedCrossRef Gattellari M, Voigt K, Butow P, Tattersall M (2002) When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J Clin Oncol 20:503–513PubMedCrossRef
13.
Zurück zum Zitat Sutherland H, Cunha R, Lockwood G, Till J (1998) What attitudes and beliefs underlie patients’ decisions about participating in chemotherapy trials? Med Decis Mak 18:61–69CrossRef Sutherland H, Cunha R, Lockwood G, Till J (1998) What attitudes and beliefs underlie patients’ decisions about participating in chemotherapy trials? Med Decis Mak 18:61–69CrossRef
14.
Zurück zum Zitat Stryker J, Wray R, Emmons K, Winer E, Demetri G (2006) Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns 63(1–2):104–109PubMedCrossRef Stryker J, Wray R, Emmons K, Winer E, Demetri G (2006) Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns 63(1–2):104–109PubMedCrossRef
15.
Zurück zum Zitat Quinn GP, Bell-Ellison BA, Bell MY et al (2008) A message of hope: creation of the faces of lung cancer project for increasing awareness of clinical trials. Eur J Cancer Care (Engl) 17(6):601–610 Quinn GP, Bell-Ellison BA, Bell MY et al (2008) A message of hope: creation of the faces of lung cancer project for increasing awareness of clinical trials. Eur J Cancer Care (Engl) 17(6):601–610
16.
Zurück zum Zitat Sandelowski M, Barroso J (2003) Classifying the findings in qualitative studies. Qual Health Res 13:905–923PubMedCrossRef Sandelowski M, Barroso J (2003) Classifying the findings in qualitative studies. Qual Health Res 13:905–923PubMedCrossRef
17.
Zurück zum Zitat Weeks JC, Cook EF, O’Day SJ, Peterson LM, Wenger N, Reding D, Harrell FE, Kussin P, Dawson NV, Connors AF Jr, Lynn J, Phillips RS (1998) Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA 279:1709–1714PubMedCrossRef Weeks JC, Cook EF, O’Day SJ, Peterson LM, Wenger N, Reding D, Harrell FE, Kussin P, Dawson NV, Connors AF Jr, Lynn J, Phillips RS (1998) Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA 279:1709–1714PubMedCrossRef
18.
Zurück zum Zitat Okuyama T (2000) Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. Journal of Pain and Symptom Management 19(1):5–14PubMedCrossRef Okuyama T (2000) Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. Journal of Pain and Symptom Management 19(1):5–14PubMedCrossRef
19.
Zurück zum Zitat Butow PN, Kazemi JN, Beeney LJ, Griffin A-M, Dunn SM, Tattersall MHN (1996) When the diagnosis is cancer: patient communication experiences and preferences. Cancer 77(12):2630–2637PubMedCrossRef Butow PN, Kazemi JN, Beeney LJ, Griffin A-M, Dunn SM, Tattersall MHN (1996) When the diagnosis is cancer: patient communication experiences and preferences. Cancer 77(12):2630–2637PubMedCrossRef
20.
Zurück zum Zitat Faller H, Lang H, Schilling S (1995) Emotional distress and hope in lung cancer patients, as perceived by patients, relatives, physicians, nurses and interviewers. Psycho-Oncology 4(1):21–31CrossRef Faller H, Lang H, Schilling S (1995) Emotional distress and hope in lung cancer patients, as perceived by patients, relatives, physicians, nurses and interviewers. Psycho-Oncology 4(1):21–31CrossRef
21.
Zurück zum Zitat Leydon GM, Boulton M, Moynihan C, Jones A, Mossman J, Boudioni M, McPherson K (2000) Cancer patients’ information needs and information seeking behaviour: in depth interview study. BMJ 320:909–913PubMedCrossRef Leydon GM, Boulton M, Moynihan C, Jones A, Mossman J, Boudioni M, McPherson K (2000) Cancer patients’ information needs and information seeking behaviour: in depth interview study. BMJ 320:909–913PubMedCrossRef
22.
Zurück zum Zitat Hollen PJ, Gralla RJ, Kris MG, Cox C (1994) Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 2(4):213–222PubMedCrossRef Hollen PJ, Gralla RJ, Kris MG, Cox C (1994) Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 2(4):213–222PubMedCrossRef
23.
Zurück zum Zitat Pinquart M, Frohlich C, Silbereisen RK (2007) Cancer patients’ perceptions of positive and negative illness-related changes. J Health Psychol 12:907–921PubMedCrossRef Pinquart M, Frohlich C, Silbereisen RK (2007) Cancer patients’ perceptions of positive and negative illness-related changes. J Health Psychol 12:907–921PubMedCrossRef
24.
Zurück zum Zitat Mitchell AJ (2007) Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol 25:4670–4681PubMedCrossRef Mitchell AJ (2007) Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol 25:4670–4681PubMedCrossRef
25.
Zurück zum Zitat Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA (2003) Health-related quality-of-life measurement in randomized clinical trials in breast cancer—taking stock. J Natl Cancer Inst 95:263–281PubMedCrossRef Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA (2003) Health-related quality-of-life measurement in randomized clinical trials in breast cancer—taking stock. J Natl Cancer Inst 95:263–281PubMedCrossRef
26.
Zurück zum Zitat Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J (2001) Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19:1885–1892PubMed Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J (2001) Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19:1885–1892PubMed
27.
Zurück zum Zitat Donovan K, Sanson-Fisher RW, Redman S (1989) Measuring quality of life in cancer patients. J Clin Oncol 7:959–968PubMed Donovan K, Sanson-Fisher RW, Redman S (1989) Measuring quality of life in cancer patients. J Clin Oncol 7:959–968PubMed
Metadaten
Titel
Lung Cancer Patients’ Decisions About Clinical Trials and the Theory of Planned Behavior
verfasst von
Gwendolyn P. Quinn, PhD
Christie L. Pratt, MA, DHSc
Kathy Bryant-George
Vicki D. Caraway, RN, BSN, MBA
Bonnie Paternoster, RN, BSN, MSN
Tere Roldan, MA, CT
Andrea Shaffer, ARNP, AOCNP
Cynthia O. Shimizu, LCSW, MABMH
Elizabeth J. Vaughn, RN, MS, OCN, CCRC
Charles Williams, MD
Gerold Bepler, MD PhD
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Education / Ausgabe 4/2011
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-010-0169-8

Weitere Artikel der Ausgabe 4/2011

Journal of Cancer Education 4/2011 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.